title: Cardiometabolic risk modification: current trends and emerging therapies.
authors.affiliation: Scottsdale Family Health, Arizona, USA.
authors.forename: Joseph L
authors.initials: JL
authors.lastname: Lillo
authors.forename: George
authors.initials: G
authors.lastname: Bray
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Woods
authors.forename: Robert R
authors.initials: RR
authors.lastname: Henry
authors.forename: Robert D
authors.initials: RD
authors.lastname: Hadley
mesh_terms: D000273:Adipose Tissue / Q000378:metabolism / Q000503:physiopathology; D000959:Antihypertensive Agents / Q000494:pharmacology; D001066:Appetite / Q000502:physiology; D001835:Body Weight / Q000187:drug effects; D002097:C-Reactive Protein / Q000032:analysis; D063385:Cannabinoid Receptor Modulators / Q000502:physiology; D002318:Cardiovascular Diseases / Q000097:blood / Q000453:epidemiology* / Q000517:prevention & control / Q000628:therapy; D008076:Cholesterol, HDL / Q000097:blood; D003920:Diabetes Mellitus / Q000453:epidemiology / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D008019:Life Style; D024821:Metabolic Syndrome / Q000097:blood / Q000453:epidemiology* / Q000517:prevention & control / Q000628:therapy; D009765:Obesity / Q000097:blood / Q000503:physiopathology; D010823:Physician Assistants; D010880:Piperidines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors / Q000502:physiology; D000077285:Rimonabant; D018570:Risk Assessment; D012307:Risk Factors; D015430:Weight Gain / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D063385:Cannabinoid Receptor Modulators; D008076:Cholesterol, HDL; D007004:Hypoglycemic Agents; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D002097:C-Reactive Protein; D000077285:Rimonabant